Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

November 27, 2023 | Last Trade: US$26.74 0.49 -1.80

HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28^th at 5:05 pm ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic and autoimmune and other devastating diseases. Visit www.celldex.com

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
This email address is being protected from spambots. You need JavaScript enabled to view it.

Patrick Till
Meru Advisors
(484) 788-8560
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$26.74
Daily Change:	-0.49 -1.80
Daily Volume:	90,923
Market Cap:	US$1.770B

November 20, 2024 Celldex Therapeutics Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases November 11, 2024 Celldex Therapeutics to Present at Upcoming Investor Conferences October 26, 2024 Celldex Therapeutics Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria October 25, 2024 Celldex Therapeutics Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 September 25, 2024 Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 LOAD MORE NEWS

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE